TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area Under the Concentration Curve (AUC) of LY2157299
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual stimulus detection with luminance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: auditory stimulus detection with parents voice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Receiving a Resource for Community Services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Eustachian tube function status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: micro Ribonucleic acids expression in the serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: micro Ribonucleic acids expression in the bone tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parkinson Disease Quality of Life Questionnaire (PDQ)-39 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dyspnea at the end of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Advanced glycation and oxidation end products (AGEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Thrombocytopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of obesity status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious adverse reactions (SARs)
Endpoint domain: Adverse events/effects
Primary endpoint: survival of participants
Endpoint domain: Mortality/survival
Primary endpoint: Rate of complete procedural success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of clinical procedural success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in cycle ergometer time trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Aerobic capacity (VO2 max) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Wingate Anaerobic Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Strength/Endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Depression status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Cognitive impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Brief QoL.BD
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Comparative DVH data for target volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparative DVH data for normal tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration Over the Entire Sampling Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination Half-life of the Drug in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in titer of thyroid autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Palliative Care referral
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Local site recurrence (LSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Reporting TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting IARs
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of body organ distribution of radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of SAR441000
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Smoking Cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With ≥ 95% Adherence to ART Medication Based on the Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of Intervention Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive diagnosis of coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brain Activation in Self-Regulation Brain Regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain Activation in Reward Brain Regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Metabolic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Drug Like/Dislike Effect at 30 Minutes Post Dose
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Tolerated Dose (MTD) of MLN0264
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Serum Concentration for MLN0264
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of conversion to sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Optimal dosing of enoxaparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of ketogenic diet
Endpoint domain: Adverse events/effects
Primary endpoint: best overall response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and local toleration
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Concentration (Cmax) of DS-5141a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) Tau of DS-5141a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration (Tmax) of DS-5141a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (T1/2) of DS-5141a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure Flow pharyngeal variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Values of dynamic indices (SVV, PPV, PVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion defect score on lung V/Q scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CTPA score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence and 10 year-incidence of SCD-related vascular complications: glomerulopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence and 10 year-incidence of SCD-related vascular complications: cardiopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence and 10 year-incidence of SCD-related vascular complications: pulmonary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence and incidence and the 10 year-incidence of SCD-related vascular complications: retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of Life Seattle Angina Questionnaire (SAQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Microbial load on dominant hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Change From Baseline in Average Sleep Onset Latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Imaging findings and medical diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity measured by step count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of MDRO Isolated
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of MRSA Isolated
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of VRE Isolated
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Ceftazidime-resistant GNB Isolated
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Ciprofloxacin-resistant GNB Isolated
Endpoint domain: Adverse events/effects
Primary endpoint: Patency of the reconstructed MHV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Young's Mania Rating Scale (YMRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants with One or More Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of premature luteinization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: NoL Index correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary GAG (glycosaminoglycans)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immunogenicity Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of Quality of Recovery questionnaire-40 (QoR-40)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: changes in cognitive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Presence of Deep Vein Thrombosis (DVT) or Pulmonary Embolus (PE)
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of prednisolone therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excessive skin healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Peak Systolic Velocities (PSV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: End Diastolic Velocities (EDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pulsatility Index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Amount of white matter damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intravascular injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in VHI-10 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fatty acid composition of milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin D in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migration of resurfacing prostheses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone density around the prosthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of transition between pediatric and adult care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: scores on Y-BOCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scores on SCID-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time between first birth and second birth
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Olerud and Molander Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Correlation between predicted and real values for post-surgical FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total Score Related to Overall Life Interference
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall clearance of lambda immunoglobulin free light chains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in cognitive function (MDI score)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in depression severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SST-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASES
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UCLA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure sensitivity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tongue inspection Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete or near complete disappearance of toenail fungus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Nasal cannula FiO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic biomarkers in lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Morbi-mortality based on Klotho variants
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Intracuff pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory confirmed influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of pain threshold measured with Potassium Pain Tester
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of pain measured with Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of pain measured with Von Frey Hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cortical excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: frequency of suctioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 Year Distant Disease Free Survival (DDFS)
Endpoint domain: Mortality/survival
Primary endpoint: Virologic impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in HIV knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Completion of exercises
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lens Geometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: de novo plaque formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Days of Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Receiving Biological Agent as Monotherapy or in Combination With csDMARDs Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average Weekly Dose of Treatment for Each Biological Agent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average Duration of Treatment for Each Biological Agent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Inability to void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: MSHQ-EJD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Depression Score Change on Geriatric Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety Score Change on State-Trait Anxiety Inventory Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vital signs and 12 lead ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 (elimination half-life)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (area under the concentration-time curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fe(total) (fraction of systemically available drug excreted into the urine over entire collection interval)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of successful placement of the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: liver fibrosis stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days monitoring is delayed past recommended follow-up interval
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Daily reported activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of MABp1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Urinary Tract Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Absorption of oral amiodarone solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radiological bone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in distensibility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depth of sedation using the RASS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maximal Oxygen Consumption (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Left Ventricular End Systolic Volume (LVESV) as Assessed Via Echo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Reversible Defect Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of HIV-positive patients with significant HIV-DNA decay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of brown adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival for Living Participants
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival for Death
Endpoint domain: Mortality/survival
Primary endpoint: Positive predictive value of 18F-DCFPyL PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weaning success from mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of wound healing disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety of donor umbilical cord blood transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of donor umbilical cord blood transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of load of traumatic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of number of aggressive acts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in experienced parental rejection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of experienced parental maltreatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of number of days spent at the landfill
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: increase in exhaled carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severity of Crohn's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes